Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.

Fiche publication

Date publication

février 2017


The Journal of clinical endocrinology and metabolism


Membres identifiés du Cancéropôle Est :
Pr DUVILLARD Laurence, Pr PETIT Jean-Michel, Pr VERGES Bruno

Tous les auteurs :
Petit JM, Cercueil JP, Loffroy R, Denimal D, Bouillet B, Fourmont C, Chevallier O, Duvillard L, Vergès B


Nonalcoholic fatty liver disease is very frequent in type 2 diabetes, with increased risk of further development of liver fibrosis. Animal studies have shown that GLP-1 receptor agonists may reduce liver lipogenesis. However, data in humans are scarce.

Mots clés

Adipose Tissue, drug effects, Adult, Aged, Diabetes Mellitus, Type 2, complications, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, administration & dosage, Liraglutide, administration & dosage, Magnetic Resonance Spectroscopy, methods, Male, Middle Aged, Non-alcoholic Fatty Liver Disease, drug therapy, Prognosis, Prospective Studies, Weight Loss, physiology


J. Clin. Endocrinol. Metab.. 2017 Feb;102(2):407-415